LAVAL, QC, May 15, 2019 /PRNewswire/ - Crescita Therapeutics
Inc. (TSX: CTX) (OTC US: CRRTF) (Crescita or the
Company), a commercial dermatology company with a portfolio of
non-prescription skincare and prescription drug products for the
treatment and care of skin conditions, diseases and their
symptoms, today announced the voting results from its 2019
Annual General and Special Meeting of Shareholders held at its
corporate headquarters in Laval,
Québec.
Election of Directors
The detailed results of the
votes for director nominees listed in the Management Information
Circular dated March 18, 2019 (the
"Circular") are as follows:
|
Director
Nominees
|
NUMBER OF
SHARES
|
PERCENTAGE OF
VOTES CAST
|
|
FOR
|
WITHHELD
|
FOR
|
WITHHELD
|
|
Daniel N.
Chicoine
|
7,456,570
|
587,320
|
92.7%
|
7.3%
|
|
David A.
Copeland
|
7,465,703
|
578,187
|
92.8%
|
7.2%
|
|
Anthony E.
Dobranowski
|
7,476,684
|
567,206
|
92.9%
|
7.1%
|
|
John C.
London
|
7,451,239
|
592,651
|
92.6%
|
7.4%
|
|
Dr. Jean-François
Tremblay
|
7,483,476
|
560,414
|
93.0%
|
7.0%
|
|
Thomas
Schlader
|
7,483,400
|
560,490
|
93.0%
|
7.0%
|
Appointment of External Auditors
Ernst and Young LLP
were appointed as external auditors of the Corporation for the next
year by a majority of the votes cast by the shareholders present,
or represented by proxy, and the directors were authorized to
determine their remuneration. The shareholders voted as
follows:
|
Outcome
|
NUMBER OF
SHARES
|
PERCENTAGE OF
VOTES CAST
|
|
FOR
|
WITHHELD
|
FOR
|
WITHHELD
|
|
Ernst & Young LLP
appointed
|
7,796,409
|
597,104
|
92.9%
|
7.1%
|
Approval of Amendments to and Continuation of Crescita's
Shareholder Rights Plan
The resolution to approve the
amendments to and the continuation of Crescita's Shareholder Rights
Plan, as described in the Circular, was approved by a majority of
the votes cast by shareholders present at the meeting or by proxy,
as follows:
|
Outcome
|
NUMBER OF
SHARES
|
PERCENTAGE OF
VOTES CAST
|
|
FOR
|
WITHHELD
|
FOR
|
WITHHELD
|
|
Shareholder Rights
Plan approved
|
7,415,592
|
628,298
|
92.2%
|
7.8%
|
About Crescita
Therapeutics Inc.
Crescita (TSX: CTX and OTC US:
CRRTF) is a publicly traded, Canadian commercial dermatology
company with a portfolio of non-prescription skincare products for
the treatment and care of skin conditions and diseases and their
symptoms and prescription drug products for the treatment of
pain. Crescita owns multiple proprietary drug delivery
platforms that support the development of patented formulations
that can facilitate the delivery of active drugs into or through
the skin. For additional information, please visit
www.crescitatherapeutics.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/crescita-therapeutics-announces-the-results-of-its-annual-general-and-special-meeting-of-shareholders-300850702.html
SOURCE Crescita Therapeutics Inc.